Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS3 | P17931 | 7/20 | 0.57 |
| ▸ | LGALS8 | O00214 | 2/20 | 0.57 |
| ▸ | LGALS4 | P56470 | 2/20 | 0.57 |
| ▸ | IGF2R | P11717 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | BMP2 | P12643 | 3/20 | 0.44 |
| ▸ | VEGFA | P15692 | 3/20 | 0.44 |
| ▸ | IFNG | P01579 | 2/20 | 0.44 |
| ▸ | FGF1 | P05230 | 1/20 | 0.44 |
| ▸ | FGF2 | P09038 | 1/20 | 0.44 |
| ▸ | SFRP1 | Q8N474 | 1/20 | 0.44 |
| ▸ | CHIA | Q9BZP6 | 1/20 | 0.43 |
| ▸ | CXCL12 | P48061 | 2/20 | 0.42 |
| ▸ | SHH | Q15465 | 2/20 | 0.42 |
| ▸ | CD69 | Q07108 | 1/20 | 0.41 |
| ▸ | LGALS1 | P09382 | 1/20 | 0.41 |
| ▸ | LGALS7; LGALS7B | P47929 | 1/20 | 0.41 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.40 |
| ▸ | PF4 | P02776 | 1/20 | 0.40 |
| ▸ | CCL2 | P13500 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15616831 | 1.00 | LGALS3 (0.57) | LGALS3LGALS8LGALS4IGF2RMAPK1 | |
| SCHEMBL18373332 | 1.00 | LGALS3 (0.57) | LGALS3LGALS8LGALS4IGF2RMAPK1 | |
| SCHEMBL21851468 | 0.86 | LGALS3 (0.68) | LGALS3LGALS8LGALS4IGF2RMAPK1 | |
| SCHEMBL16921639 | 0.85 | IGF2R (0.52) | LGALS3LGALS8LGALS4IGF2RBMP2 | |
| SCHEMBL21851348 | 0.85 | LGALS3 (0.64) | LGALS3LGALS8LGALS4IGF2RMAPK1 | |
| SCHEMBL17832654 | 0.84 | LGALS3 (0.69) | LGALS3LGALS8LGALS4IGF2RMAPK1 | |
| SCHEMBL17822291 | 0.84 | LGALS3 (0.69) | LGALS3LGALS8LGALS4IGF2RMAPK1 | |
| SCHEMBL17822271 | 0.84 | LGALS3 (0.69) | LGALS3LGALS8LGALS4IGF2RMAPK1 | |
| SCHEMBL19513256 | 0.84 | IGF2R (0.53) | LGALS3LGALS8LGALS4IGF2RBMP2 | |
| SCHEMBL16925416 | 0.84 | IGF2R (0.53) | LGALS3LGALS8LGALS4IGF2RBMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10221205-B2 | Tetragalnac and peptide containing conjugates and methods for delivery of oligonucleotides | SIRNA THERAPEUTICS, INC. (US) | 2019-03-05 | — | — | US | disclosed |
| US-20180079769-A1 | NOVEL TETRAGALNAC AND PEPTIDE CONTAINING CONJUGATES AND METHODS FOR DELIVERY OF OLIGONUCLEOTIDES | BANK OF AMERICA, N.A. | 2018-03-22 | — | — | US | disclosed |
| US-9840531-B2 | Tetragalnac and peptide containing conjugates and methods for delivery of oligonucleotides | SIRNA THERAPEUTICS, INC. (US) | 2017-12-12 | — | — | US | disclosed |
| US-20170306324-A1 | NOVEL TETRAGALNAC AND PEPTIDE CONTAINING CONJUGATES AND METHODS FOR DELIVERY OF OLIGONUCLEOTIDES | BANK OF AMERICA, N.A. | 2017-10-26 | — | — | US | disclosed |
| US-20170233731-A1 | NOVEL TETRAGALNAC CONTAINING CONJUGATES AND METHODS FOR DELIVERY OF OLIGONUCLEOTIDES | BANK OF AMERICA, N.A. | 2017-08-17 | — | — | US | disclosed |
| US-9655976-B2 | Tetragalnac and peptide containing conjugates and methods for delivery of oligonucleotides | SIRNA THERAPEUTICS, INC. (US) | 2017-05-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170233731-A1 | NOVEL TETRAGALNAC CONTAINING CONJUGATES AND METHODS FOR DELIVERY OF OLIGONUCLEOTIDES | CSGALNACT1, GALNT1, FUT6 | LGALS3 89/4885LGALS8 54/4885LGALS4 91/4885 |
| US-10221205-B2 | Tetragalnac and peptide containing conjugates and methods for delivery of oligonucleotides | GALNT3, B3GAT3, CSGALNACT1 | LGALS3 20/4885LGALS8 43/4885LGALS4 66/4885 |
| US-20180079769-A1 | NOVEL TETRAGALNAC AND PEPTIDE CONTAINING CONJUGATES AND METHODS FOR DELIVERY OF OLIGONUCLEOTIDES | GALNT3, CSGALNACT1, FUT6 | LGALS3 33/4885LGALS8 42/4885LGALS4 78/4885 |
| US-20170306324-A1 | NOVEL TETRAGALNAC AND PEPTIDE CONTAINING CONJUGATES AND METHODS FOR DELIVERY OF OLIGONUCLEOTIDES | GALNT3, CSGALNACT1, FUT6 | LGALS3 33/4885LGALS8 42/4885LGALS4 78/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.